AbbVie (ABBV) Stock: What the $10.9 Billion Apogee Deal Means for Earnings and Pipeline
TLDR
- AbbVie completed its acquisition of Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion
- Apogee’s lead drug, zumilokibart, targets IL-13 and showed about two-thirds of atopic dermatitis patients achieved skin clearance in Phase 2 trials
- The pipeline also includes APG273, a combination therapy targeting both IL-13 and TSLP for asthma treatment
- AbbVie expects the deal to dilute adjusted EPS by $0.14 in 2026 and $0.46 in 2027, with accretion not starting until 2032
- AbbVie reaffirmed its full-year 2026 adjusted diluted EPS guidance of $13.87 to $14.07
AbbVie (ABBV) closed its acquisition of Apogee Therapeutics on September 3, 2026, paying $135.11 per share in cash for a total equity value of around $10.9 billion. Apogee’s stock stopped trading on that date.
The deal adds a pipeline of immunology drugs to AbbVie’s existing portfolio. The focus is on inflammatory and immunological diseases including atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
